PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-66.42%
Negative ROE while TRAW stands at 76.06%. Joel Greenblatt would investigate capital misallocation or uncompetitive positioning.
-40.44%
Both firms have negative ROA. Martin Whitman would investigate if the market environment is extremely challenging.
-61.73%
Negative ROCE while TRAW is at 232.47%. Joel Greenblatt would look for capital misallocation or cyclical downturn.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.